These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35017530)

  • 1. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
    Al Kaabi N; Oulhaj A; Al Hosani FI; Al Mazrouei S; Najim O; Hussein SE; Abdalla JS; Fasihuddin MS; Hassan AA; Elghazali G; Al Rumaithi A; Al Azazi J; Weber S; Beiram R; Parekh KA; Sheek-Hussein M; Yang Y; Xiaoming Y; Quliang J; Eltantawy I; Mahmoud S; Koshy A; Xiao P; Ganesan S; Elamin W; Zaher W
    Sci Rep; 2022 Jan; 12(1):490. PubMed ID: 35017530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
    Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
    Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P
    Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
    Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
    Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.
    Sedaghat N; Etemadifar M; Lotfi N; Sayahi F; Chitsaz A; Salari M; Ghasemi Movaghar A
    Front Immunol; 2023; 14():952911. PubMed ID: 36895555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccination and major cardiovascular and haematological adverse events in Abu Dhabi: retrospective cohort study.
    Pimentel MAF; Shaikh M; Al Safi M; Naqvi Y; Khan S
    Nat Commun; 2024 Jun; 15(1):5490. PubMed ID: 38944652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered T-cell receptor β repertoire in adults with SARS CoV-2 inactivated vaccine of BBIBP-CorV.
    Quan Z; Qi A; Ma S; Li Y; Chen H; Yu X; Dong T; Li K; Qiu Y
    Mol Immunol; 2023 Oct; 162():54-63. PubMed ID: 37647774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
    Joudi M; Moradi Binabaj M; Porouhan P; PeyroShabany B; Tabasi M; Fazilat-Panah D; Khajeh M; Mehrabian A; Dehghani M; Welsh JS; Keykhosravi B; Akbari Yazdi A; Ariamanesh M; Ghasemi A; Ferns G; Javadinia SA
    Front Endocrinol (Lausanne); 2022; 13():798975. PubMed ID: 35299966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
    Park S; Gatchalian KK; Oh H
    Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
    Kaabi NA; Yang YK; Du LF; Xu K; Shao S; Liang Y; Kang Y; Su JG; Zhang J; Yang T; Hussein S; ElDein MS; Yang SS; Lei W; Gao XJ; Jiang Z; Cong X; Tan Y; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Hou JW; Lei ZH; Xiao P; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM
    Nat Commun; 2022 Jun; 13(1):3654. PubMed ID: 35760812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country.
    Macchia A; Ferrante D; Angeleri P; Biscayart C; Mariani J; Esteban S; Tablado MR; de Quirós FGB
    JAMA Netw Open; 2021 Oct; 4(10):e2130800. PubMed ID: 34714342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
    Al Kaabi N; Zhang Y; Xia S; Yang Y; Al Qahtani MM; Abdulrazzaq N; Al Nusair M; Hassany M; Jawad JS; Abdalla J; Hussein SE; Al Mazrouei SK; Al Karam M; Li X; Yang X; Wang W; Lai B; Chen W; Huang S; Wang Q; Yang T; Liu Y; Ma R; Hussain ZM; Khan T; Saifuddin Fasihuddin M; You W; Xie Z; Zhao Y; Jiang Z; Zhao G; Zhang Y; Mahmoud S; ElTantawy I; Xiao P; Koshy A; Zaher WA; Wang H; Duan K; Pan A; Yang X
    JAMA; 2021 Jul; 326(1):35-45. PubMed ID: 34037666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial.
    Solaymani-Dodaran M; Basiri P; Moradi M; Gohari K; Sheidaei A; Ahi M; Ghafoori Naeeni F; Ansarifar A; Rahimi Z; Gholami F; Karimi Rahjerdi A; Hamidi Farahani R; Naderi Saffar K; Ghasemi S; Shooshtari A; Honari M; Mozafari A; Khodaverdloo S; Forooghizadeh M
    Virol J; 2023 Jul; 20(1):154. PubMed ID: 37464440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
    Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
    PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine.
    Mahmoud S; Ganesan S; Sharif-Askari NS; Cantarutti F; Wilson H; Ogrodzki P; Halwani R; Alkaabi N; Zaher WA
    Curr Med Res Opin; 2022 Dec; 38(12):2069-2075. PubMed ID: 36274640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
    Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA
    J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
    Musa S; Merdrignac L; Skocibusic S; Nedic R; Cilovic-Lagarija S; Kissling E
    Vaccine; 2024 May; 42(15):3467-3473. PubMed ID: 38644077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India.
    Malhotra S; Mani K; Lodha R; Bakhshi S; Mathur VP; Gupta P; Kedia S; Sankar J; Kumar P; Kumar A; Ahuja V; Sinha S; Guleria R; ; Dua A; Ahmad S; Sathiyamoorthy R; Sharma A; Sakya T; Gaur V; Chaudhary S; Sharma S; Madan D; Gupta A; Virmani S; Gupta A; Yadav N; Sachdeva S; Sharma S; Singh S; Pandey A; Singh M; Jhurani D; Sarkar S; Lokade AK; Mohammad A; Pandit S; Dubey R; Singh AK; Gohar N; Soni D; Bhattacharyya A; Rai S; Tummala S; Gupta I; Shukla S
    JAMA Netw Open; 2022 Jan; 5(1):e2142210. PubMed ID: 34994793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.